The inclusion of HCRT and EPO informatics would suppress the correlation to R2 values of 0.973 (N = 9) and 0.927 (N = 8), respectively, suggesting that HCRT drugs could be a better choice for treating Late-onset Alzheimer's disease as compared to EPO drugs. This evidence concerns the gene EPO and early-onset autosomal dominant Alzheimer disease.